Encyclopedia of Pathology

Living Edition
| Editors: J.H.J.M. van Krieken

Ductal Carcinoma In Situ

  • Isabella Castellano
  • Jasna Metovic
Living reference work entry
DOI: https://doi.org/10.1007/978-3-319-28845-1_4706-1

Synonyms

Definition

Ductal carcinoma in situ (DCIS) is a neoplastic proliferation confined to the mammary ductal-lobular system, which is surrounded by a myoepithelial layer and a basal membrane. DCIS covers a heterogeneous group of diseases characterized by subtle to marked cytological atypia, without any invasion of the stromal tissue (Lakhani et al. 2012).

Clinical Features

Incidence

DCIS incidence gradually and constantly increased over the past decades (from 5.8 per 100,000 women in 1975 to 34.4 per 100,000 women in 2014), according to data of the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program (SEER 2014). DCIS consequently constitutes around 20% of all breast cancer diagnoses.

The widespread use of mammography, as well as implementation of national breast screening programs (Ernster and Barclay 1997), contributed to the diagnosis...

This is a preview of subscription content, log in to check access.

References and Further Reading

  1. Abba, M. C., Drake, J. A., Hawkins, K. A., et al. (2004). Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Research, 6, R499–R513.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Abba, M. C., Gong, T., Lu, Y., et al. (2015). A molecular portrait of high-grade ductal carcinoma in situ. Cancer Research, 75, 3980–3990.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Adriance, M. C., Inman, J. L., Petersen, O. W., et al. (2005). Myoepithelial cells: Good fences make good neighbors. Breast Cancer Research, 7, 190–197.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Allinen, M., Beroukhim, R., Cai, L., et al. (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 6, 17–32.CrossRefPubMedGoogle Scholar
  5. Anderson, W. F., & Devesa, S. S. (2005). In situ male breast carcinoma in the surveillance, epidemiology, and end results database of the National Cancer Institute. Cancer, 104, 1733–1741.CrossRefPubMedGoogle Scholar
  6. Aubele, M., Cummings, M., Walsch, A., et al. (2000). Heterogeneous chromosomal aberrations in intraductal breast lesions adjacent to invasive carcinoma. Analytical Cellular Pathology, 20, 17–24.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bellamy, C. O., McDonald, C., Salter, D. M., et al. (1993). Noninvasive ductal carcinoma of the breast: The relevance of histologic categorization. Human Pathology, 24, 16–23.CrossRefPubMedGoogle Scholar
  8. Böcker, W. (2006). Preneoplasia of the breast. A new conceptual approach to proliferative breast disease. Munich: Elsevier GmbH.Google Scholar
  9. Bombonati, A., & Sgroi, D. C. (2011). The molecular pathology of breast cancer progression. Journal of Pathology, 223, 307–317.CrossRefPubMedGoogle Scholar
  10. Bratthauer, G. L., Moinfar, F., Stamatakos, M. D., et al. (2002). Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. Human Pathology, 33, 620–627.CrossRefPubMedGoogle Scholar
  11. Casasent, A. K., Edgerton, M., & Navin, N. E. (2017). Genome evolution in ductal carcinoma in situ: Invasion of the clones. Journal of Pathology, 241, 208–218.CrossRefPubMedGoogle Scholar
  12. Castellano, I., Marchiò, C., Tomatis, M., et al. (2010). Micropapillary ductal carcinoma in situ of the breast: An inter-institutional study. Modern Pathology, 23, 260–269.CrossRefPubMedGoogle Scholar
  13. Comparison of Operative to Monitoring and Endocrine Therapy (COMET). Trial For Low Risk DCIS (COMET). https://clinicaltrials.gov/ct2/show/NCT02926911
  14. Curigliano, G., Disalvatore, D., Esposito, A., et al. (2015). Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Annals of Oncology, 26, 682–687.CrossRefPubMedGoogle Scholar
  15. Decensi, A., Puntoni, M., Pruneri, G., et al. (2011). Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prevention Research, 4, 1181–1189.CrossRefPubMedGoogle Scholar
  16. Elsayegh, N., Kuerer, H. M., Lin, H., et al. (2014). Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Annals of Oncology, 21, 3466–3472.CrossRefGoogle Scholar
  17. Elshof, L. E., Tryfonidis, K., Slaets, L., et al. (2015). Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – the LORD study. European Journal of Cancer, 51, 1497–1510.CrossRefPubMedGoogle Scholar
  18. EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group, Bijker, N., et al. (2006). Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Journal of Clinical Oncology, 24, 3381–3387.CrossRefGoogle Scholar
  19. Erbas, B., Provenzano, E., Armes, J., et al. (2006). The natural history of ductal carcinoma in situ of the breast: A review. Breast Cancer Research and Treatment, 97, 135–144.CrossRefPubMedGoogle Scholar
  20. Ernster, V. L., & Barclay, J. (1997). Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: A dilemma. Journal of the National Cancer Institute Monographs, 22, 151–156.CrossRefGoogle Scholar
  21. Ernster, V. L., Barclay, J., Kerlikowske, K., et al. (2000). Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Archives of Internal Medicine, 160, 953–958.CrossRefPubMedGoogle Scholar
  22. Ernster, V. L., Ballard-Barbash, R., Barlow, W. E., et al. (2002). Detection of ductal carcinoma in situ in women undergoing screening mammography. Journal of the National Cancer Institute, 94, 1546–1554.CrossRefPubMedGoogle Scholar
  23. Francis, A., Fallowfield, L., & Rea, D. (2015). The LORIS trial: Addressing overtreatment of ductal carcinoma in situ. Clinical Oncology, 27, 6–8.CrossRefPubMedGoogle Scholar
  24. Galimberti, V., Monti, S., & Mastropasqua, M. G. (2013). DCIS and LCIS are confusing and outdated terms. They should be abandoned in favor of ductal intraepithelial neoplasia (DIN) and lobular intraepithelial neoplasia (LIN). Breast, 22, 431–435.CrossRefPubMedGoogle Scholar
  25. Giuseppetti, G. M., Boria, F., & Baldassare, S. (2018). DCIS imaging. In C. Mariotti (Ed.), Ductal carcinoma in situ (pp. 39–57). Cham: Springer.CrossRefGoogle Scholar
  26. Greenwood, H. I., Heller, S. L., Kim, S., et al. (2013). Ductal carcinoma in situ of the breasts: Review of MR imaging features. Radiographics, 33, 1569–1588.CrossRefPubMedGoogle Scholar
  27. Hannafon, B. N., Sebastiani, P., de las Morenas, A., et al. (2011). Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Research, 13, R24.CrossRefPubMedGoogle Scholar
  28. Holmes, P., Lloyd, J., Chervoneva, I., et al. (2011). Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone. Cancer, 117, 3650–3657.CrossRefPubMedGoogle Scholar
  29. Kim, S. Y., Jung, S. H., Kim, M. S., et al. (2015). Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer. Oncotarget, 6, 7597–7607.PubMedPubMedCentralGoogle Scholar
  30. King, M. T., Winters, Z. E., Olivotto, I. A., et al. (2017). Patient-reported outcomes in ductal carcinoma in situ: A systematic review. European Journal of Cancer, 71, 95–108.CrossRefPubMedGoogle Scholar
  31. Kong, I., Narod, S. A., Taylor, C., et al. (2014). Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: A population-based outcomes analysis. Current Oncology, 21, e96–e104.CrossRefPubMedPubMedCentralGoogle Scholar
  32. Kuerer, H. M., Buzdar, A. U., Mittendorf, E. A., et al. (2011). Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer, 117, 39–47.CrossRefPubMedGoogle Scholar
  33. Lakhani, S. R., Ellis, I. O., Schnitt, S. J., et al. (2012). WHO classification of tumors of the breast. Lyon: International Agency for Research on Cancer.Google Scholar
  34. Lopez-Garcia, M. A., Geyer, F. C., Lacroix-Triki, M., et al. (2010). Breast cancer precursors revisited: Molecular features and progression pathways. Histopathology, 57, 171–192.CrossRefPubMedGoogle Scholar
  35. Lyman, G. H., Temin, S., Edge, S. B., et al. (2014). Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology, 32, 1365–1383.CrossRefPubMedGoogle Scholar
  36. Mardekian, S. K., Bombonati, A., & Palazzo, J. P. (2016). Ductal carcinoma in situ of the breast: The importance of morphologic and molecular interactions. Human Pathology, 49, 114–123.CrossRefPubMedGoogle Scholar
  37. Margolese, R. G., Cecchini, R. S., Julian, T. B., et al. (2016). Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): A randomised, double-blind, phase 3 clinical trial. Lancet, 387, 849–856.CrossRefPubMedGoogle Scholar
  38. McCormick, B., Winter, K., Hudis, C., et al. (2015). RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. Journal of Clinical Oncology, 33, 709–715.CrossRefPubMedPubMedCentralGoogle Scholar
  39. Mustonen, M., Raunio, H., Pääkkö, P., et al. (1997). The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions. Histopathology, 31, 347–354.CrossRefPubMedGoogle Scholar
  40. Page, D. L., & Rogers, L. W. (1992). Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Human Pathology, 23, 1095–1097.CrossRefPubMedGoogle Scholar
  41. Patchefsky, A. S., Schwartz, G. F., Finkelstein, S. D., et al. (1989). Heterogeneity of intraductal carcinoma of the breast. Cancer, 63, 731–741.CrossRefPubMedGoogle Scholar
  42. Pilewskie, M., & Morrow, M. (2018). Margins in breast cancer: How much is enough? Cancer, 124, 1335–1341.CrossRefPubMedGoogle Scholar
  43. Pluchinotta, A. (2018). History of the DCIS of the breast and the evolution of knowledge based on ductal tree anatomy. In C. Mariotti (Ed.), Ductal Carcinoma in situ (pp. 1–23). Cham: Springer.Google Scholar
  44. Polyak, K., & Hu, M. (2005). Do myoepithelial cells hold the key for breast tumor progression? Journal of Mammary Gland Biology and Neoplasia, 10, 231–247.CrossRefPubMedGoogle Scholar
  45. Rakha, E. A., Miligy, I. M., Gorringe, K. L., et al. (2017). Invasion in breast lesions: The role of the epithelial-stroma barrier. Histopathology, 72, 1075.  https://doi.org/10.1111/his.13446.CrossRefGoogle Scholar
  46. Ravaioli, S., Tumedei, M. M., Foca, F., et al. (2017). Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy. International Journal of Experimental Pathology, 98, 289–295.CrossRefPubMedGoogle Scholar
  47. Reis-Filho, J. S., & Lakhani, S. R. (2003). The diagnosis and management of pre-invasive breast disease: Genetic alterations in pre-invasive lesions. Breast Cancer Research, 5, 313–319.CrossRefPubMedPubMedCentralGoogle Scholar
  48. Reis-Filho, J. S., Simpson, P. T., Gale, T., et al. (2005). The molecular genetics of breast cancer: The contribution of comparative genomic hybridization. Pathology, Research and Practice, 201, 713–725.CrossRefPubMedGoogle Scholar
  49. Rominger, M., Berg, D., Frauenfelder, T., et al. (2016). Which factors influence MRI-pathology concordance of tumour size measurements in breast cancer? European Radiology, 26, 1457–1465.CrossRefPubMedGoogle Scholar
  50. Rutter, C. E., Park, H. S., Killelea, B. K., et al. (2015). Growing use of mastectomy for ductal carcinoma-in situ of the breast among young women in the United States. Annals of Surgical Oncology, 22, 2378–2386.CrossRefPubMedGoogle Scholar
  51. Shackney, S. E., & Silverman, J. F. (2003). Molecular evolutionary patterns in breast cancer. Advances in Anatomic Pathology, 10, 278–290.CrossRefPubMedGoogle Scholar
  52. Siziopikou, K. P., Anderson, S. J., Cobleigh, M. A., et al. (2013). Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Research and Treatment, 142, 415–421.CrossRefPubMedPubMedCentralGoogle Scholar
  53. Solin, L. J., Gray, R., Baehner, F. L., et al. (2013). A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. Journal of the National Cancer Institute, 105, 701–710.CrossRefPubMedPubMedCentralGoogle Scholar
  54. Staerkle, R. F., Lenzlinger, P. M., Suter, S. L., et al. (2006). Synchronous bilateral ductal carcinoma in situ of the male breast associated with gynecomastia in a 30-year-old patient following repeated injections of stanozolol. Breast Cancer Research and Treatment, 97, 173–176.CrossRefPubMedGoogle Scholar
  55. Surveillance, Epidemiology, and End Results (SEER) Program. (2014). National Cancer Institute. https://seer.cancer.gov/csr/1975_2014/
  56. Tavassoli, F. A., & Devilee, P. (2003). World Health Organization classification of tumors of the breast. Lyon: International Agency for Research on Cancer.Google Scholar
  57. Tot, T., & Gere, M. (2008). Radiological-pathological correlation in diagnosing breast carcinoma: The role of pathology in the multimodality era. Pathology & Oncology Research, 14, 173–178.CrossRefGoogle Scholar
  58. Verkooijen, H. M., Fioretta, G., De Wolf, C., et al. (2002). Management of women with ductal carcinoma in situ of the breast: A population-based study. Annals of Oncology, 13, 1236–1245.CrossRefPubMedGoogle Scholar
  59. Vincent-Salomon, A., Lucchesi, C., Gruel, N., et al. (2008). Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clinical Cancer Research, 14, 1956–1965.CrossRefPubMedGoogle Scholar
  60. Volinia, S., Galasso, M., Sana, M. E., et al. (2012). Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proceedings of the National Academy of Sciences of the United States of America, 109, 3024–3029.CrossRefPubMedPubMedCentralGoogle Scholar
  61. Wai, E. S., Lesperance, M. L., Alexander, C. S., et al. (2011). Predictors of local recurrence in a population-based cohort of women with ductal carcinoma in situ treated with breast conserving surgery alone. Annals of Surgical Oncology, 18, 119–124.CrossRefPubMedGoogle Scholar
  62. Wapnir, I. L., Dignam, J. J., Fisher, B., et al. (2011). Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. Journal of the National Cancer Institute, 103, 478–488.CrossRefPubMedPubMedCentralGoogle Scholar
  63. Yates, L. R., Gerstung, M., Knappskog, S., et al. (2015). Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nature Medicine, 21, 751–759.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medical SciencesUniversity of TurinTurinItaly
  2. 2.Department of OncologyUniversity of TurinTurinItaly